3rd Edition Drug Safety Symposium 2025 – Dubai Chapter

Revolutionizing Drug Safety: Key Takeaways from the 3rd Edition Drug Safety Symposium 2025 – Dubai Chapter

(L-R: Dr. Katya Nabeel Ailabouni, Pharmacovigilance Officer, Emirates Drug Establishment; Dr. Wesal AlHaqaish, Director General Technical Assistant, Jordan Food & Drug Administration; Dr. Manal Younus, Director, Iraqi Pharmacovigilance Center; Dr. Omar Aimer, President, North America Chapter – IsoP; Dr. (Prof.) Nouzha Lazli, Head, Centre National de Pharmacovigilance – Algeria; Dr. (Prof) Riadh DAGHFOUS, GENERAL DIRECTOR, Centre National de Pharmacovigilance Tunisien and Dr. Rania Mouchantaf, Executive Director, Health Canada)

Caption:
How AI, Patient Advocacy, and Global Collaboration Are Redefining Pharmacovigilance – Insights from Dubai’s Premier 3rd Edition Drug Safety Symposium 2025!

In A Box:

Collaboration took center stage as experts echoed a resounding message—this is the most exciting time for pharmacovigilance. With the rise of real-world and 'near-world' data, AI-driven insights, and cutting-edge regulatory advancements, the industry stands at the brink of transformation. The symposium wasn’t just a conference; it was a catalyst for redefining drug safety, forging partnerships, and shaping the future of patient-centric pharmacovigilance.

19 February 2025, Dubai: The 3rd Edition Drug Safety Symposium 2025 – Dubai Chapter concluded with resounding success, solidifying its position as a premier platform for advancing pharmacovigilance and patient safety on a global scale. Hosted in the vibrant city of Dubai, the event brought together over 20 distinguished speakers, regulatory & PV leaders and industry experts from nine countries to foster cross-border collaboration and drive innovation in drug safety.

A Platform for Global Collaboration and Innovation

This year’s symposium was a melting pot of ideas, featuring in-depth discussions on critical topics such as evolving regulatory frameworks, PV strategies, risk management plans, and the role of PSMF. A key highlight was the exploration of AI in pharmacovigilance, with experts delving into how AI can revolutionize safety monitoring and enhance patient outcomes. The event underscored the importance of integrating cutting-edge technology with traditional practices to create a more robust and efficient drug safety ecosystem.

Patient-Centricity Takes Center Stage
The symposium opened with a powerful session titled "Let’s Talk About Patients First," setting the tone for a patient-first approach to drug safety. It also included a groundbreaking patient advocacy panel that provided a platform for patient representatives to share their experiences, challenges, and expectations. This session reinforced the need to embed the patient perspective into pharmacovigilance practices, emphasizing that drug safety is not just about compliance but about improving real lives.

Hands-On Learning and Practical Insights
Eminence Group, the organizer of the event, curated a unique experience by incorporating interactive workshops and real-world case studies. Attendees engaged in mock audits, navigated complex regulatory scenarios, and participated in hands-on sessions designed to translate knowledge into actionable strategies. They also indulged in Risk Management Workshop where they focused on aspects like risk identification, mitigation, safety communication and aRMMs. These workshops were led by industry veterans, ensuring that participants left with practical tools to enhance their drug safety frameworks.

AWINSA Life Sciences, led by Dr. Sanjeev Miglani, Founder and Director, served as the esteemed exhibit partner, bringing their expertise in providing end-to-end pharmacovigilance services—encompassing both clinical trial and post-marketing safety solutions—to the forefront of the symposium, significantly enriching the event’s success.

A Refreshing Digital Detox
In a world dominated by screens, the Eminence Digital Detox Session was a breath of fresh air. This innovative initiative encouraged attendees to disconnect from technology, engage in meaningful face-to-face networking, and embrace mindfulness. The session highlighted the importance of well-being in professional settings, aligning with Eminence Group’s commitment to fostering both intellectual and personal growth.

Meet the Visionaries: Spotlight on the Speakers
The symposium featured an impressive lineup of 19 speakers, each contributing their expertise to shape the future of pharmacovigilance. Here are the key voices that made the event unforgettable:
1.Dr. Omar Aimer, President, North America Chapter - ISoP
2.Dr. Ahmed Hegazy, MD, Pvigilant Health
3.Dr. Raghda Mohamed Hassan, Patient Safety and Pharmacovigilance Cluster Lead, Takeda
4.Dr. Rania Mouchantaf, Executive Director, Health Canada
5.Dr. Katya Nabeel Ailabouni, Pharmacovigilance Officer, Emirates Drug Establishment  
6.Dr. Manal Younus, Director, Iraqi Pharmacovigilance Center
7.Dr. (Prof.) Nouzha Lazli, Head, Centre National de Pharmacovigilance – Algeria
8.Dr. (Prof) Riadh DAGHFOUS, GENERAL DIRECTOR, Centre National de Pharmacovigilance Tunisien
9.Dr. Wesal AlHaqaish, Director General Technical Assistant, Jordan Food & Drug Administration
10.Dr. Tarik Messaoud, Medical Director, Acces Clinical research
11.Dr. Gopal Muralidharan, Head – Global Pharmacovigilance and Clinical Affairs, Arcolab
12.Dr. Maha El Temamy, Head of Pharmacovigilance Hub at Roche CEETRIS, Middle East & Africa, Roche
13.Dr. Laila Fatima, Associate Director, Novartis
14.Rania Haggag, Associate Director – Global Pharmacovigilance & Business Excellence, Organon
15.Dr. Samah Ragab, Regulatory Affairs and Pharmacovigilance Director, Middle East, North and West Africa, Organon
16.Dr. Humaira Qureshi , Co-Founder, One World Life Sciences
17.Sherif Khattab, Director Medical Affairs ERTs & PKU, International Region, BioMarin
18.Youmna Ouraybi, Patient Advocacy Lead and Founder, Ana Fareed
19.Gayatri Singh, Founder, Gmantra
20.Dr. Moin Don, Founder, PVCon
21.Prof Mirza Baig, Associate Dean – Clinical Research, Dubai Collage of Pharmacy for Girls

Pre-Event Webinar
In the lead-up to the 3rd Edition Drug Safety Symposium 2025 – Dubai Chapter, a Pre-Event Webinar set the stage for insightful discussions, offering a glimpse into the key themes that would shape the symposium. Featuring renowned industry experts, the webinar served as an engaging knowledge-sharing platform, preparing participants for the deep-dive sessions ahead. Dr. Moin Don delivered a compelling session on the evolving regulatory landscape and the critical role of AI in proactive pharmacovigilance, emphasizing how AI can help in early risk detection and mitigation enhancing patient safety. Meanwhile, Prof. Mirza Baig explored role of clinical research in PV highlighting the need for continuous learning to keep pace with the dynamic advancements in pharmacovigilance. This pre-event knowledge exchange laid a strong foundation, ensuring attendees arrived at the symposium well-informed and ready for high-level discussions.

A Legacy of Impact
The Drug Safety Symposium 2025 left an indelible mark on the industry, sparking conversations that will shape the future of pharmacovigilance. By prioritizing collaboration, innovation, and patient-first principles, the event reinforced the UAE and the Middle East’s growing influence in the global drug safety landscape. The insights gained from this symposium will undoubtedly drive smarter regulations, stronger safety measures, and a more patient-centric approach to pharmacovigilance.

As we look forward to the next edition, one thing is clear: the boundaries of drug safety are being pushed further than ever before. Stay tuned for more groundbreaking developments in the world of pharmacovigilance and stay tuned as we launch the 4th Edition Drug Safety Symposium 2025 – India Chapter.
 
For further information
Ravnish@eminencemedia.in